Chugai Pharmaceutical (CHGCY) versus The Competition Critical Review

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Chugai Pharmaceutical to related companies based on the strength of its earnings, valuation, analyst recommendations, risk, institutional ownership, profitability and dividends.

Analyst Recommendations

This is a breakdown of current recommendations for Chugai Pharmaceutical and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chugai Pharmaceutical 0 3 1 1 2.60
Chugai Pharmaceutical Competitors 7870 13817 25857 1043 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 30.33%. Given Chugai Pharmaceutical’s competitors higher probable upside, analysts plainly believe Chugai Pharmaceutical has less favorable growth aspects than its competitors.

Dividends

Chugai Pharmaceutical pays an annual dividend of $0.24 per share and has a dividend yield of 1.1%. Chugai Pharmaceutical pays out 25.0% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.4% and pay out 48.2% of their earnings in the form of a dividend.

Insider and Institutional Ownership

0.0% of Chugai Pharmaceutical shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Chugai Pharmaceutical and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Chugai Pharmaceutical $8.41 billion $2.91 billion 23.18
Chugai Pharmaceutical Competitors $18.34 billion $3.19 billion 560.54

Chugai Pharmaceutical’s competitors have higher revenue and earnings than Chugai Pharmaceutical. Chugai Pharmaceutical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Chugai Pharmaceutical has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Chugai Pharmaceutical’s competitors have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.

Profitability

This table compares Chugai Pharmaceutical and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chugai Pharmaceutical 35.63% 24.91% 20.67%
Chugai Pharmaceutical Competitors -2,391.71% -204.89% -14.89%

Summary

Chugai Pharmaceutical competitors beat Chugai Pharmaceutical on 8 of the 15 factors compared.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products. The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.